Uncovering NK Cell Sabotage in Gut Diseases Via Single Cell Transcriptomics

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2025 Jan 3

PMID 39752457

Authors

Hansong Lee

Dai Sik Ko

Hye Jin Heo

Seung Eun Baek

Eun Kyoung Kim

Eun Jung Kwon

Junho Kang

Yeuni Yu

Ninib Baryawno

Kihun Kim

Dongjun Lee

Yun Hak Kim

Affiliations

Soon will be listed here.

Abstract

The identification of immune environments and cellular interactions in the colon microenvironment is essential for understanding the mechanisms of chronic inflammatory disease. Despite occurring in the same organ, there is a significant gap in understanding the pathophysiology of ulcerative colitis (UC) and colorectal cancer (CRC). Our study aims to address the distinct immunopathological response of UC and CRC. Using single-cell RNA sequencing datasets, we analyzed the profiles of immune cells in colorectal tissues obtained from healthy donors, UC patients, and CRC patients. The colon tissues from patients and healthy participants were visualized by immunostaining followed by laser confocal microscopy for select targets. Natural killer (NK) cells from UC patients on medication showed reduced cytotoxicity compared to those from healthy individuals. Nonetheless, a UC-specific pathway called the BAG6-NCR3 axis led to higher levels of inflammatory cytokines and increased the cytotoxicity of NCR3+ NK cells, thereby contributing to the persistence of colitis. In the context of colorectal cancer (CRC), both NK cells and CD8+ T cells exhibited significant changes in cytotoxicity and exhaustion. The GALECTIN-9 (LGALS9)-HAVCR2 axis was identified as one of the CRC-specific pathways. Within this pathway, NK cells solely communicated with myeloid cells under CRC conditions. HAVCR2+ NK cells from CRC patients suppressed NK cell-mediated cytotoxicity, indicating a reduction in immune surveillance. Overall, we elucidated the comprehensive UC and CRC immune microenvironments and NK cell-mediated immune responses. Our findings can aid in selecting therapeutic targets that increase the efficacy of immunotherapy.

References

Aran D, Looney A, Liu L, Wu E, Fong V, Hsu A . Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019; 20(2):163-172. PMC: 6340744. DOI: 10.1038/s41590-018-0276-y. View

Boland B, He Z, Tsai M, Olvera J, Omilusik K, Duong H . Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020; 5(50). PMC: 7733868. DOI: 10.1126/sciimmunol.abb4432. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Kaluzna A, Olczyk P, Komosinska-Vassev K . The Role of Innate and Adaptive Immune Cells in the Pathogenesis and Development of the Inflammatory Response in Ulcerative Colitis. J Clin Med. 2022; 11(2). PMC: 8780689. DOI: 10.3390/jcm11020400. View

Arnhold J . Host-Derived Cytotoxic Agents in Chronic Inflammation and Disease Progression. Int J Mol Sci. 2023; 24(3). PMC: 9918110. DOI: 10.3390/ijms24033016. View

Lee H, Joo J, Sohn D, Kang J, Yu Y, Park H . Single-cell RNA sequencing reveals rebalancing of immunological response in patients with periodontitis after non-surgical periodontal therapy. J Transl Med. 2022; 20(1):504. PMC: 9635198. DOI: 10.1186/s12967-022-03702-2. View

Scott P, Anderson K, Singhania M, Cormier R . Cystic Fibrosis, CFTR, and Colorectal Cancer. Int J Mol Sci. 2020; 21(8). PMC: 7215855. DOI: 10.3390/ijms21082891. View

Raad M, Chams N, Sharara A . New and Evolving Immunotherapy in Inflammatory Bowel Disease. Inflamm Intest Dis. 2018; 1(2):85-95. PMC: 5988105. DOI: 10.1159/000445986. View

Dorrington A, Selinger C, Parkes G, Smith M, Pollok R, Raine T . The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020; 14(9):1316-1329. DOI: 10.1093/ecco-jcc/jjaa053. View

10.

Pogge von Strandmann E, Simhadri V, von Tresckow B, Sasse S, Reiners K, Hansen H . Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007; 27(6):965-74. DOI: 10.1016/j.immuni.2007.10.010. View

11.

Ndhlovu L, Lopez-Verges S, Barbour J, Jones R, Jha A, Long B . Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012; 119(16):3734-43. PMC: 3335380. DOI: 10.1182/blood-2011-11-392951. View

12.

Russo P, Ferreira G, Cardozo L, Burger M, Arias-Carrasco R, Maruyama S . CEMiTool: a Bioconductor package for performing comprehensive modular co-expression analyses. BMC Bioinformatics. 2018; 19(1):56. PMC: 5819234. DOI: 10.1186/s12859-018-2053-1. View

13.

Lee H, Park S, Yun J, Seo C, Ahn J, Cha H . Deciphering head and neck cancer microenvironment: Single-cell and spatial transcriptomics reveals human papillomavirus-associated differences. J Med Virol. 2024; 96(1):e29386. DOI: 10.1002/jmv.29386. View

14.

Olen O, Erichsen R, Sachs M, Pedersen L, Halfvarson J, Askling J . Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020; 395(10218):123-131. DOI: 10.1016/S0140-6736(19)32545-0. View

15.

Dassler-Plenker J, Reiners K, van den Boorn J, Hansen H, Putschli B, Barnert S . RIG-I activation induces the release of extracellular vesicles with antitumor activity. Oncoimmunology. 2016; 5(10):e1219827. PMC: 5087302. DOI: 10.1080/2162402X.2016.1219827. View

16.

Neurath M . Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019; 20(8):970-979. DOI: 10.1038/s41590-019-0415-0. View

17.

Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J . Ulcerative colitis. Lancet. 2016; 389(10080):1756-1770. PMC: 6487890. DOI: 10.1016/S0140-6736(16)32126-2. View

18.

Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K . ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012; 23(10):2479-2516. DOI: 10.1093/annonc/mds236. View

19.

Avramidou M, Angst F, Angst J, Aeschlimann A, Rossler W, Schnyder U . Epidemiology of gastrointestinal symptoms in young and middle-aged Swiss adults: prevalences and comorbidities in a longitudinal population cohort over 28 years. BMC Gastroenterol. 2018; 18(1):21. PMC: 5787318. DOI: 10.1186/s12876-018-0749-3. View

20.

Meier J, Sturm A . Current treatment of ulcerative colitis. World J Gastroenterol. 2011; 17(27):3204-12. PMC: 3158396. DOI: 10.3748/wjg.v17.i27.3204. View